Nadolol

Nadolol is a polar and hydrophilic, non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. It is a long-acting beta-blocker, which displays activity against beta-1 and beta-2 receptors. It has a preference for beta-1 receptors, which are predominantly located in the heart, thereby inhibiting the effects of catecholamines and causing a decrease in heart rate and blood pressure. Nadolol's inhibition of beta-1 receptors in the heart and kidney leads to its effects on lowering blood pressure. Its inhibition of beta-2 receptors, which are mainly located in the bronchial smooth muscle of the airways, leads to airway constriction similar to that seen in asthma. Product References: (1) D.B. Evans, et al., Eur. J. Pharmacol. 35, 17 (1976) , (2) W. Frishman, Am. Heart J. 99, 124 (1980) (Review) , (3) R.C. Heel, et al., Drugs 20, 1 (1980) (Review) , (4) W.H. Frishman, N. Engl. J. Med. 305, 678 (1981) (Review) , (5) H. Peng, et al., 383, 209 (2011) Appearance: White to off-white powder. Solubility: Soluble in DMSO (20mg/ml) or DMF. Identity: Determined by 1H-NMR. InChi Key: VWPOSFSPZNDTMJ-UCWKZMIHSA-N Smiles: O[C@H]1[C@@H](O)CC2=C(OCC(O)CNC(C)(C)C)C=CC=C2C1